<DOC>
	<DOCNO>NCT00971763</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride , cyclophosphamide , vincristine sulfate , prednisolone , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving one drug ( combination chemotherapy ) together rituximab may kill cancer cell . PURPOSE : This phase II trial study give gemcitabine hydrochloride , cyclophosphamide , vincristine sulfate , prednisolone together rituximab see well work treat patient newly diagnose diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride , Cyclophosphamide , Vincristine Sulfate , Prednisolone , Rituximab Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine whether rituximab , combination non-cardiotoxic chemotherapy comprise gemcitabine hydrochloride , cyclophosphamide , vincristine sulfate , prednisolone , efficacious group patient unfit CHOP chemotherapy . OUTLINE : This multicenter study . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 ; cyclophosphamide IV , vincristine sulfate IV , rituximab IV day 1 ; oral prednisolone daily day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20positive diffuse large Bcell nonHodgkin lymphoma ( DLBCL ) accord current WHO classification , include morphological variant Newly diagnose disease Bulky stage IAIV disease No nonbulky stage IA disease Measurable disease Not eligible CHOP chemotherapy due impaired cardiac function Cardiac status allow administration 8 course RCHOP chemotherapy , define 1 follow criterion : Ejection fraction le 50 % assess either ECHO MUGA scan NYHA class IIIIV No highgrade transformation lowgrade lymphoma No symptomatic central nervous system meningeal involvement lymphoma No AIDSrelated lymphoma PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 3 month Platelet count &gt; 100 x 10^9/L WBC &gt; 3 x 10^9/L Neutrophils &gt; 1.5 x 10^9/L ( unless elevate level attribute bone marrow infiltration lymphoma ) Serum bilirubin &lt; 50 Î¼mol/L Transaminases &lt; 2.5 time upper limit normal ( unless elevate level attribute lymphoma ) Glomerular filtration rate &gt; 30 mL/min Not pregnant nursing Fertile patient must use effective contraception No concurrent uncontrolled medical condition No active malignant disease , nonmelanotic skin cancer carcinoma situ uterine cervix , within past 10 year No positive serology HIV No medical psychiatric condition compromise patient 's ability give inform consent PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , investigational drug indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>